Review examines high-volume hemodiafiltration outcomes and practical delivery

A review in the Journal of the American Society of Nephrology examines high-volume hemodiafiltration (HDF) with online production of substitution fluid as an alternative to conventional high-flux hemodialysis. Drawing on randomized trials, individual participant data meta-analyses, and real-world studies, the authors discuss mortality, hospitalization, patient-reported outcomes, and practical treatment delivery. This is an evidence overview, not a new clinical trial.

The authors report that high-volume HDF reduces all-cause mortality and hospitalization compared with high-flux hemodialysis, with benefits appearing to increase with achieved convective volume. They also describe evidence suggesting better patient-reported outcomes and cost-effectiveness. The supplied abstract does not provide study populations, sample sizes, absolute risks, effect estimates, or specific convection-volume targets, limiting assessment of the magnitude and consistency of benefit.

For clinical delivery, the review emphasizes vascular access, blood flow rate, filtration fraction, treatment duration, dialyzer characteristics, and machine technology. The authors state that high-volume post-dilution HDF is feasible within standard thrice-weekly schedules and recommend monitoring middle-molecule removal and patient-centered outcomes alongside small-solute clearance. Implementation requires infrastructure, staff training, and quality assurance. Proposed individualized prescriptions and technology-supported monitoring are future directions rather than established outcome improvements.